Oct 12 2022

Halberd Progresses from Eliminating Top Brain Disease Antigens from CSF To Eradication of Interleukin-6 From Human Blood Serum

By |2022-10-11T20:09:20-04:00October 12th, 2022|Investor News, News, Press Releases, Uncategorized|0 Comments

Excess IL-6 is associated with inflammation in rheumatoid arthritis, MS, some cancers and neurodegenerative diseases. Jackson Center, PA, October 12, 2022 – Halberd Corporation (OTC-PINK: "HALB”) demonstrated the removal of Interleukin-6 (IL-6) from human blood serum during in-vitro laboratory studies.  Excess Interleukin-6 in the blood has been linked to numerous adverse health conditions. Unlike Halberd’s ...

Aug 1 2021

Halberd Corporation Adds Blood-Borne Disease Treatment Capability With Addition Of Noted Nephrologist

By |2021-08-10T21:46:53-04:00August 1st, 2021|Uncategorized|0 Comments

Jackson Center, PA, August 11, 2021 – Halberd Corporation’s (OTC-PINK: "HALB") today confirmed the addition of Dr. Ned Kronfol as a member of its Scientific Advisory Board.  Dr. Kronfol is certified by the American Board of Internal Medicine and retired in 2019 as Adjunct Clinical Professor from the William Carey University College of Osteopathic Medicine. ...

Apr 19 2021

Halberd Corporation Moves Radio Frequency (RF) Disease Elimination Effort Forward With the Addition of Youngstown State University (YSU) and Dr. William G. Sturrus

By |2021-04-18T21:39:58-04:00April 19th, 2021|Featured, Investor News, News, Uncategorized|0 Comments

Brings Critical Radio Frequency Wave Expertise to Company’s Effort Jackson Center, PA, April 19, 2021 – Halberd Corporation (OTC-PINK: "HALB") is pleased to announce Youngstown State University’s (YSU) Dr. William G. Sturrus will lead the Radio Frequency (RF) research on Halberd’s Disease Elimination multi-organization Task Force.  Dr. Sturrus, who has 30 years of radio ...

Apr 12 2021

Halberd Corporation Files International Patent Cooperation Treaty (PCT) Application on Covid-19 Inflammatory Cytokine Storm Treatment

By |2021-04-11T20:02:28-04:00April 12th, 2021|Featured, Investor News, News, Uncategorized|0 Comments

Jackson Center, PA, April 12, 2021 – Halberd Corporation (OTC-PINK: "HALB") filed an International Patent Cooperation Treaty (PCT) application for coverage of the invention titled, “Covid-19 Inflammatory Cytokine Storm Treatment.”  The Patent Cooperation Treaty has over 150 participating countries and allows an inventor to seek patent protection in numerous countries simultaneously. William A. Hartman, Chairman, ...

Mar 30 2021

Halberd Corporation’s Scientific Breakthrough: Conjugating Metallic Particles to SARS-CoV-2 and E. Coli Antigens

By |2021-03-29T20:24:19-04:00March 30th, 2021|Featured, Investor News, News, Uncategorized|0 Comments

Paves Way for Disease Elimination by Radio Frequency Waves Jackson Center, PA, March 30, 2021 – Halberd Corporation (OTC-PINK: "HALB") has successfully conjugated (joined) metallic nanoparticles with its patent-pending SARS-CoV-2 antibody, while still maintaining the antibody’s antigen-neutralizing properties.  This was a key scientific hurdle to overcome in implementing its patent-pending extracorporeal disease eradication methodology through ...

Go to Top